ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025
Breaking New Ground: Novel Intralesional Amphotericin B for Mucormycosis.
Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-intravenous Amphotericin B: A Review of Localized Administration Routes.Infectious diseases and therapy · 2026Review
- Acute Invasive Fungal Rhino-Orbital Sinusitis: Current Concepts and Controversies.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis, a severe fungal infection with high morbidity and mortality rates, particularly affects immunocompromised individuals. Standard treatments involving debridement and systemic antifungals often encounter resistance, especially in cutaneous forms due to systemic toxicity and poor tissue penetration of Amphotericin B. This case series investigates the effectiveness of intralesional Amphotericin B for targeted delivery with minimal systemic side effects. Three cases are presented: a 50-year-old man with invasive mucormycosis in the sinuses and frontal bone, a 10-year-old boy with poorly controlled diabetes and periorbital mucormycosis, and a 62-year-old man with diabetes and periorbital cellulitis from invasive fungal sinusitis. All underwent surgical debridement followed by systemic and intralesional Amphotericin B. The intralesional treatment, administered over seven consecutive days, resulted in significant clinical and radiological improvements, with complete resolution of cutaneous involvement. This series marks the first documentation of intralesional Amphotericin B's efficacy in mucormycosis, suggesting it as a promising alternative for refractory cases. Previous studies on cutaneous leishmaniasis also support its potential, showing high recovery rates with minimal side effects. Further research is needed to confirm these findings and optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.